Rapamycin and metformin are real medicines with legitimate clinical uses. They are also studied in aging research. Those facts should not be combined into the claim that either is a proven longevity prescription for otherwise healthy adults.
The relevant decision concerns the actual indication, evidence and risks for the individual. This guide does not provide an experimental regimen, advise changing an existing prescription or present use outside an established indication as risk-free.
What are the medicines normally used for?
EMA describes sirolimus, also called rapamycin, as an immunosuppressive medicine used for selected transplant and lung-disease indications. It acts on mTOR-related signaling. These authorized uses do not constitute an authorization to treat normal aging.
The NHS describes metformin principally in diabetes care and other selected clinical circumstances. Its benefit-risk balance for a person with an established indication differs from speculative use by someone without that condition.
Do not stop an indicated medicine because an aging study raises questions about a different population. The prescriber should interpret the research in the context of the condition being treated.
What have human rapamycin trials shown?
The 2025 PEARL trial examined intermittent rapamycin over 48 weeks. Its primary visceral-fat outcome did not improve significantly. Some secondary or subgroup measures were favorable, but the trial did not test human life extension.
A 2026 randomised exercise trial in older adults found no improvement in its primary functional outcome from adding sirolimus. Some sensitivity analyses favored placebo, and adverse-event burden was higher with sirolimus. The study was exploratory and small, so it should neither be exaggerated into universal harm nor ignored when discussing possible benefit.
These findings show why mTOR biology and animal lifespan experiments do not settle the clinical question. Human outcomes, exposure schedules and participant health need their own evidence.
Can metformin and exercise have trade-offs?
In the MASTERS randomised trial, healthy older adults taking metformin gained less muscle from a resistance-training program than participants receiving placebo. The result concerns a specific intervention and population, not a reason for everyone with diabetes to stop treatment.
A medicine and an activity can each have potential value without their combination producing the sum of both effects. Claims that a drug necessarily amplifies every healthy habit need testing.
Ask whether a study involved people with diabetes, otherwise healthy adults or another selected group. An observational association between medicine use and survival cannot remove differences between the people receiving and not receiving treatment.
What would stronger longevity evidence need to show?
It should establish meaningful outcomes in an appropriate human population, with adequate follow-up and a clear balance of benefits and harms. A short-term laboratory or aging-clock change is not equivalent to fewer disabling illnesses or longer survival.
Check primary outcomes separately from exploratory findings. A positive subgroup result can generate a useful hypothesis while still requiring confirmation. Trial registration, publication and commercial enthusiasm are not interchangeable with demonstrated clinical benefit.
Ask who funded the study and whether the investigators have relevant commercial interests. Disclosure does not invalidate research, but it makes independent replication particularly valuable.
What makes supervision important?
EMA lists sirolimus risks including infections, delayed wound healing, blood-cell changes and altered metabolic or organ-function results. The risk profile in established uses cannot simply be assumed identical to an intermittent experimental schedule, but neither can those concerns be dismissed.
Metformin also requires attention to suitability, side effects, kidney function and interacting circumstances. The exact assessment and monitoring belong with the prescribing clinician, not an online stack or dosing calculator.
Before any off-label proposal, request the clinical rationale, evidence uncertainties, monitoring plan, stopping criteria and arrangements for adverse effects. A prescription is not proof that the proposed anti-aging benefit is established. Buying medicines from unverified online sources introduces additional product risks.
Questions to ask
What established problem would this treat for me?
Distinguish a recognized clinical indication from research or speculative prevention in healthy adults.
Is there a proven lifespan benefit?
The human trials discussed here do not establish that benefit. Ask for the actual endpoint supporting any stronger claim.
Does SENSES prescribe these medicines for longevity?
This article is educational, not confirmation of prescribing or endorsement of an experimental regimen. Any actual service must be explicitly confirmed.
Continue with physical-longevity training and aging-marker limitations.
Why does the population studied matter when considering a longevity medicine?
A medicine can have a favorable benefit-risk balance for an established disease without providing the same balance to someone without that disease. The question is not simply whether the compound has been used safely before, but whether its expected benefit justifies its risks in the proposed situation.
The PERMET randomised trial examined metformin in 202 people with peripheral artery disease but without diabetes. After six months, it did not improve the primary six-minute walking outcome or the secondary outcomes compared with placebo. This does not support using metformin to improve walking in that population.
It also does not show that metformin lacks value for its established indications. A trial in people without diabetes answers a different question from clinical diabetes management. Someone taking it for a recognized condition should discuss research with the prescriber rather than stopping treatment because an unrelated longevity claim is uncertain.
For rapamycin, a transplant regimen, a lung-disease indication and an experimental intermittent schedule are also different contexts. Safety experience in one cannot be assumed identical in another. The relevant evidence needs to match the product, exposure, population and outcome being proposed.
This is why personalized care requires more than adjusting a dose to a biological-age result. The clinician should identify a defensible clinical objective, explain the evidence and uncertainty, and consider whether the same goal can be addressed through a better-supported approach.
How can you interpret a small trial without overstating either benefit or harm?
Start with the prespecified primary analysis. In the RAPA-EX-01 trial, the main analysis did not demonstrate an added functional benefit from sirolimus, while sensitivity analyses raised concern about smaller gains with the drug. That is more informative than selecting whichever analysis produces the strongest headline.
A non-significant finding does not prove that the true effect is exactly zero. It means the study did not establish the proposed difference under that analysis. Equally, an encouraging subgroup result does not establish a benefit for everyone. Consider the uncertainty around the estimate and whether a larger confirmatory study is needed.
Review adverse events with the same care. The number of participants reporting an event and the total number of events are different measures. Severity, possible relationship to treatment and follow-up duration matter too. A short study with few participants cannot rule out every uncommon risk.
Ask whether the outcome is meaningful for the decision. A change in a laboratory marker, lean-tissue estimate or questionnaire may be interesting, but it is not interchangeable with fewer disabling illnesses or longer survival. The name healthspan in a paper’s title does not change what was actually measured.
Finally, ask how the proposed clinical service uses the uncertainty. A responsible discussion includes the possibility of no benefit, the option not to proceed and a clear monitoring plan. Repeated testing should have a defined purpose rather than act as reassurance that an experimental approach must be working.
Frequently asked questions about rapamycin, metformin and aging research
Does off-label prescribing mean a treatment has been proven for longevity?
No. Prescribing outside an authorized indication and demonstrating benefit for that use are separate matters. Ask what evidence supports the proposal and which local rules apply. A prescription should not be presented as proof that an anti-aging outcome is established or that the treatment carries no meaningful risk.
Should I stop metformin because a trial suggested less muscle gain?
Do not stop an indicated medicine independently. The exercise trial concerns a specific population and intervention, while your prescription may address an established medical need. Discuss your training goals and concerns with the prescriber so the complete benefit-risk picture can be considered.
Can an aging-clock test identify who should take rapamycin?
A commercial score does not automatically establish an indication or predict treatment benefit. Ask whether the test has been validated for that decision and whether changing the result improves meaningful outcomes. Our biological-age guide explains why measurement and clinical usefulness are different requirements.
Does intermittent use remove the risks of an immunosuppressive medicine?
No risk-free conclusion follows from a different schedule. Exposure may change, but the benefit and safety of the proposed regimen still need evidence. Ask the clinician to explain known concerns, uncertainty and monitoring. Do not copy an online schedule or modify it around exercise without appropriate medical oversight.
Can several longevity medicines be combined to cover more aging pathways?
Separate mechanistic arguments do not establish the benefit or safety of a combination. Medicines can interact with one another and with existing care. Request evidence for the actual proposal rather than accepting a pathway diagram as a clinical plan. More compounds are not automatically a more comprehensive prevention strategy.
What should be clarified before travel or a procedure?
Tell the responsible clinical teams about all medicines and ask for instructions relevant to the planned care. Infection, wound healing, kidney function and other considerations may affect decisions depending on the treatment. Do not independently stop or restart a medicine based on a general internet rule.
Why do funding and conflicts of interest belong in the discussion?
They help readers understand the context of research and the importance of independent confirmation. A commercial involvement does not automatically invalidate a study, but it should not be hidden. The strongest interpretation rests on design, results and replication rather than either dismissing or accepting research solely because of its sponsor.
What is a better starting point than an experimental prescription?
Begin with the health problem or preventive decision you actually need to address. Established cardiovascular care, sleep treatment, adequate nutrition or appropriate activity may be relevant depending on the assessment. Those decisions should not be delayed while an uncertain medicine is used to pursue a general promise of rejuvenation.
How should an existing prescription be documented during a SENSES stay?
Provide the medicine, indication, prescriber and relevant monitoring arrangements. Clarify who can make changes and how information will return to the usual clinician with consent. Educational coverage of aging research does not establish that SENSES will prescribe, supervise or alter any particular medicine.
Evidence and sources
- EMA: Sirolimus indications and risks
- NHS: Metformin
- PEARL trial, 2025
- RAPA-EX-01 trial, 2026
- MASTERS trial
General educational information. Do not start, stop or alter prescription treatment without the responsible clinician.